Vaccine Research

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

Latest Research & Publications

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Uncertainty and Risk in HTA Decision Making

The Distribution of the EQ-5D-5L Index in Patient Populations

Improving Efficiency and Resource Allocation in Future Cancer Care

Four Case Studies to Explore the Added Value of Oxford AHSN

All Publications

Filter results by

Socio-Economic Value of Adult Immunisation Programmes

Valuing Vaccines: The Economics of Vaccines & Immunisations

Filter results by

Share on Mastodon